AllAnalyst Report
logoMorningstarOctober 27, 2020

Eli Lilly and Company: Eli Lilly Posts Slightly Weak Q3, but Looks Undervalued and Well-Positioned for Long-Term Growth

Symbols
LLY
Sector(s)
Healthcare
Rating
Premium
Current Price
$144.90
Fair Value
Premium
Economic Moat
Premium
Stewardship
Premium
Summary

Eli Lilly is a drug company with a focus on neuroscience, endocrinology, oncology, and immunology. Lilly's key products include Alimta and Verzenio for cancer; Jardiance, Trulicity, Humalog, and Humulin for diabetes; and Taltz and Olumiant for immunology.

Premium
Subscribe to Yahoo Finance Premium for full access
Read the latest independent research including analyst forecasts, ratings on the US economy, and more. Get individual company and overall sector level recommendations.
Try Premium FREE